Keros Therapeutics (KROS) PT Raised to $42 at Jefferies, Following Earnings
Tweet
Share
E-mailGet Alerts KROS Hot Sheet
Price: $11.10 --0%
Rating Summary:
8 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 11 | New: 19
Rating Summary:
8 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 11 | New: 19
Join SI Premium – FREE
Jefferies analyst Eun K. Yang raised the price target on Keros Therapeutics (NASDAQ: KROS) to $42.00 (from $37.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Upgrades BWP Trust (BWP:AU) to Neutral
- Sichuan Kelun-Biotech Biopharmaceutical (6990:HK) PT Raised to HK$677 at JPMorgan
- Fuyao Glass Industry Group Co Ltd. (3606:HK) PT Raised to R$60 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Jefferies & Co, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
